Effects of Allicin Pretreatment on Anti-oxidation Ability and Delayed Onset Muscle Soreness

NCT07812688 | Completed

• 1 other identifier: GXNU20230801003
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

To investigate the effects of allicin pretreatment on delayed onset muscle soreness (DOMS), muscle function, and oxidative stress following eccentric exercise

Conditions

Delayed Onset Muscle Soreness

Outcome Measures

Primary Outcomes (1)

• Subjective Pain Sensation

  Subjective pain sensation was assessed using the Visual Analog Scale (VAS), which ranges from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate a worse outcome (greater pain intensity). Measurements were taken to evaluate the degree of Delayed Onset Muscle Soreness (DOMS) at the following time points: pre-medication (Pre-drug), pre-exercise (Pre-exercise), immediately post-exercise (Post-exercise), 24 hours post-exercise (24 h), 48 hours post-exercise (48 h), and 72 hours post-exercise (72 h).

  Pre-medication, pre-exercise, immediately post-exercise, 24 hours, 48 hours, and 72 hours post-exercise.

Secondary Outcomes (5)

• Calf Circumference

  Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

• Vertical Jump Height

  Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

• Posterior Calf Muscle Strength

  Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

• Knee Joint Range of Motion

  Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

• Biochemical Index Sample Collection and Testing

  Before medication, before exercise, immediately after exercise, 24 hours post-exercise, 48 hours post-exercise, and 72 hours post-exercise

Study Arms (2)

allicin group

EXPERIMENTAL

The allicin group received garlic extract as an intervention

Drug: allicin

placebo group

PLACEBO COMPARATOR

The placebo group received a placebo

Drug: placebo

Interventions

placebo DRUG

The placebo was made by filling empty capsules with starch. The two were identical in packaging, appearance, color, and taste. Group B: Subjects took the same dose of placebo (starch capsules) at 80 mg/d during the same period.

placebo group

allicin DRUG

The garlic extract capsules were purchased from Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd. (National Drug Approval No. H32025683). Subjects took garlic extract capsules orally every day for 15 days before exercise, once per day, 4 capsules each time, equivalent to 80 mg/d

allicin group

Eligibility Criteria

• Age: 18 Years - 24 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants voluntarily agreed to join the study and signed informed consent forms.
• Male participants aged between 18 and 24 years.
• Physically healthy, with no history of major or congenital diseases.
• Normal results in routine physical examinations, with no history of severe musculoskeletal injuries.
• Physical fitness levels equivalent to those of typical university students majoring in sports.
• During the entire experiment, participants must not engage in any intense physical activities other than the specified exercise protocol.

You may not qualify if:

• Participants with poor compliance or those who violate the experimental requirements.
• Participants who are unwilling to cooperate and fail to complete the required data collection for the experiment.
• Participants who have taken anti-inflammatory or steroid medications within the past month.
• Participants who have experienced musculoskeletal injuries within the past two months.

Sponsors & Collaborators

• Guangxi Normal University: lead

Study Sites (1)

Guangxi Normal University

Guilin, China

Location

MeSH Terms

Interventions

allicin

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Senior Technician

Study Record Dates

• First Submitted: September 1, 2026
• First Posted: September 10, 2026
• Study Start: April 1, 2024
• Primary Completion: June 30, 2024
• Study Completion: June 30, 2024
• Last Updated: September 10, 2026

Record last verified: 2026-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)